MCMCB Pro
J9075

J9075Injection, cyclophosphamide, not otherwise specified, 5 mg

HCPCSActiveBETOS O1D

J9075 is a HCPCS Level II code for injection, cyclophosphamide, not otherwise specified, 5 mg. It belongs to the Drugs Administered Other Than Oral Method section. Whether Medicare pays it depends on the coverage rule below.

Medicare coverage: Special coverage instructions apply

There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.

From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.

Physician fee schedule statusE

Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).

Global period: XXX

Want the dollar amount for your locality? The fee calculator applies your GPCI and the current conversion factor.

Medically Unlikely Edits — units per day

The most units of J9075 Medicare will pay on one date of service. Bill more on a single line and it is denied. The limit is not the same in every setting, so the row that matters is the one matching the claim you are building.

practitioner
1500 units
MAI 3 — Date of Service Edit: Clinical · Prescribing Information
outpatient
1500 units
MAI 3 — Date of Service Edit: Clinical · Prescribing Information
DME supplier
1500 units
MAI 3 — Date of Service Edit: Clinical · Prescribing Information

The adjudication indicator decides whether exceeding the limit is worth appealing at all: MAI 1 is a line edit you can support with documentation, MAI 3 is a date-of-service edit that is also appealable, and MAI 2 is absolute — no documentation overrides it. CMS MUE 2026Q3.

The CMS record for J9075

Long descriptor
Injection, cyclophosphamide, not otherwise specified, 5 mg

The official wording. This is what the code means.

Short descriptor
Inj, cyclophosphamide, nos

CMS's 28-character form, which is what shows up on a remittance advice.

Added
April 1, 2024

When CMS introduced the code.

BETOS
O1D

Berenson-Eggers Type of Service — CMS's own analytic grouping.

Pricing indicator
51 — Other

Drugs.

Codes adjacent to J9075

HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If J9075 is not quite right, the correct code is very often within a few positions of it.

  • J9063Injection, mirvetuximab soravtansine-gynx, 1 mg
  • J9064Injection, cabazitaxel (sandoz), not therapeutically equivalent to j9043, 1 mg
  • J9065Injection, cladribine, per 1 mg
  • J9070Cyclophosphamide, 100 mgterminated
  • J9071Injection, cyclophosphamide (auromedics), 5 mg
  • J9072Injection, cyclophosphamide (frindovyx), 5 mg
  • J9073Injection, cyclophosphamide (dr. reddy's), 5 mg
  • J9074Injection, cyclophosphamide (sandoz), 5 mg
  • J9076Injection, cyclophosphamide (baxter), 5 mg
  • J9098Injection, cytarabine liposome, 10 mgterminated
  • J9100Injection, cytarabine, 100 mg
  • J9118Injection, calaspargase pegol-mknl, 10 units
  • J9119Injection, cemiplimab-rwlc, 1 mg
  • J9120Injection, dactinomycin, 0.5 mg
  • J9130Dacarbazine, 100 mg
  • J9144Injection, daratumumab, 10 mg and hyaluronidase-fihj

Questions about J9075

What is HCPCS code J9075?

J9075 is a HCPCS Level II code for injection, cyclophosphamide, not otherwise specified, 5 mg. It sits in the Drugs Administered Other Than Oral Method section.

Does Medicare cover J9075?

The CMS HCPCS file marks J9075 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.

How is J9075 paid under the physician fee schedule?

J9075 carries PFS status code E. Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).

HCPCS Level II2026Q3-Jul· effective July 1, 2026